- cafead   Mar 22, 2023 at 10:42: AM
via Things are heating up at Flare Therapeutics, with Pfizer, Eli Lilly and Novartis all adding fuel to the biotech’s fire in a new $123 million financing round.
“We’re the only company focused on transcription factors as prime therapeutic targets,” Flare CEO Amit Rakhit, M.D., told Fierce Biotech in an interview.
article source
“We’re the only company focused on transcription factors as prime therapeutic targets,” Flare CEO Amit Rakhit, M.D., told Fierce Biotech in an interview.
article source